Clinical-stage biotech Cassava Sciences (NASDAQ:SAVA) responded to charges of research wrongdoing on Wednesday after it was reported that the U.S. Department of Justice had opened a criminal investigation into the company's experimental Alzheimer's treatment. According to Chief Executive Remi Barbier, No government agency had notified Sciences (NASDAQ:SAVA) that it has identified supporting evidence of research misconduct or any other wrongdoing, and for good reason — there is no supporting evidence for charges of research misconduct.
The Texas-based business cited a 2021 disclosure involving a widely rumored government subpoena. Cassava (NASDAQ:SAVA) stated that the claims of research ...
Read The Full Article On StockStreetNews.com
Get early insight on hidden secret gems on StockStreetNews . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by StockStreetNews is subject to our Terms Of Use and Disclaimer .
For further details see:
Cassava Disputes Charges Regarding the Government Investigation; Slams Short Sellers